CANNABINOIDS AND EPILEPSY FEBRERO 2019

This message contains My NCBI what's new results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).
 
1. Front Neurol. 2019 Jan
Corrigendum: Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Pamplona FA(1), da Silva LR(2), Coan AC(3). Author information: (1)Entourage Phytolab, São Paulo, Brazil. (2)Bedrocan Brasil, São Paulo, Brazil. (3)UNICAMP, Campinas, Brazil. Erratum for Front Neurol. 2018 Sep 2. Behav Brain Res. 2019 Jan Cannabidiol modulates phosphorylated rpS6 signalling in a zebrafish model of Tuberous Sclerosis Complex. Serra I(1), Scheldeman C(2), Bazelot M(3), Whalley BJ(4), Dallas ML(5), de Witte PAM(6), Williams CM(7). Author information: (1)School of Psychology and Clinical Language Sciences, University of Reading, Reading, United Kingdom; School of Pharmacy, University of Reading, Reading, United Kingdom. Electronic address: Esta dirección de correo electrónico está siendo protegida contra los robots de spam. Necesita tener JavaScript habilitado para poder verlo.. (2)Laboratory for Molecular Biodiscovery, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium; Neurogenetics research group, VUB, Brussels, Belgium. Electronic address: Esta dirección de correo electrónico está siendo protegida contra los robots de spam. Necesita tener JavaScript habilitado para poder verlo.. (3)GW Research Ltd. Sovereign House, Vision Park, Histon, Cambridge, United Kingdom. Electronic address: Esta dirección de correo electrónico está siendo protegida contra los robots de spam. Necesita tener JavaScript habilitado para poder verlo.. (4)School of Pharmacy, University of Reading, Reading, United Kingdom; GW Research Ltd. Sovereign House, Vision Park, Histon, Cambridge, United Kingdom. Electronic address: Esta dirección de correo electrónico está siendo protegida contra los robots de spam. Necesita tener JavaScript habilitado para poder verlo.. (5)School of Pharmacy, University of Reading, Reading, United Kingdom. Electronic address: Esta dirección de correo electrónico está siendo protegida contra los robots de spam. Necesita tener JavaScript habilitado para poder verlo.. (6)Laboratory for Molecular Biodiscovery, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium. Electronic address: Esta dirección de correo electrónico está siendo protegida contra los robots de spam. Necesita tener JavaScript habilitado para poder verlo.. (7)School of Psychology and Clinical Language Sciences, University of Reading, Reading, United Kingdom. Electronic address: Esta dirección de correo electrónico está siendo protegida contra los robots de spam. Necesita tener JavaScript habilitado para poder verlo.. Tuberous sclerosis complex (TSC) is a rare disease caused by mutations in the TSC1 or TSC2 genes and is characterized by widespread tumour growth, intractable epilepsy, cognitive deficits and autistic behaviour. CBD has been reported to decrease seizures and inhibit tumour cell progression, therefore we sought to determine the influence of CBD on TSC pathology in zebrafish carrying a nonsense mutation in the tsc2 gene. CBD treatment from 6 to 7 days post-fertilization (dpf) induced significant anxiolytic actions without causing sedation. Furthermore, CBD treatment from 3 dpf had no impact on tsc2-/- larvae motility nor their survival. CBD treatment did, however, reduce the number of phosphorylated rpS6 positive cells, and their cross-sectional cell size. This suggests a CBD mediated suppression of mechanistic target of rapamycin (mTOR) activity in the tsc2-/- larval brain. Taken together, these data suggest that CBD selectively modulates levels of phosphorylated rpS6 in the brain and additionally provides an anxiolytic effect. This is pertinent given the alterations in mTOR signalling in experimental models of TSC. Additional work is necessary to identify upstream signal modulation and to further justify the use of CBD as a possible therapeutic strategy to manage TSC. Copyright © 2019. Published by Elsevier B.V. 3. Ugeskr Laeger. 2017 Oct Opstrup P(1), Olsen M, Nysom K, Uldall PV, Walther-Larsen S. Author information: The Danish parliament has decided to establish a four-year pilot scheme for medical treatment with cannabis. We increasingly experience requests from parents for medical treatment with cannabis of children and have the impression that a growing number of parents treat their children with illegally acquired cannabis products for various conditions. We summarize the sparse evidence regarding effects, side effects and long-term effects of medical treatment with cannabis in children and adolescents. At present, cannabis should very rarely be considered as part of medical treatment for children and adolescents. 4. Psychosomatics. 2017 Mar New-Onset Refractory Status Epilepticus Associated With the Use of Synthetic Cannabinoids. Patel NA(1), Jerry JM(2), Jimenez XF(3), Hantus ST(4). Author information: (1)Department of Adult Psychiatry, Cleveland Clinic, Cleveland, OH. (2)Cleveland Clinic Alcohol and Drug Recovery Center, Cleveland Clinic Lutheran Hospital, Cleveland, OH; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH. (3)Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH; Consultation-Liaison Psychiatry, Cleveland Clinic, Cleveland, OH. (4)Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH; Epilepsy Center, Cleveland Clinic, Cleveland, OH.